Ligand Pharmaceuticals Rating Reiterated by Cantor Fitzgerald (LGND)
Ligand Pharmaceuticals (NASDAQ:LGND)‘s stock had its “sell” rating reiterated by stock analysts at Cantor Fitzgerald in a report issued on Wednesday, American Banking and Market News reports. They currently have a $37.00 price target on the stock. Cantor Fitzgerald’s target price would suggest a potential downside of 21.34% from the company’s current price.
LGND has been the subject of a number of other recent research reports. Analysts at MLV Capital raised their price target on shares of Ligand Pharmaceuticals (NASDAQ:LGND) to $62.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at Summer Street raised their price target on shares of Ligand Pharmaceuticals (NASDAQ:LGND) from $36.00 to $64.00 in a research note to investors on Friday, August 2nd. They now have a “buy” rating on the stock. Finally, analysts at Roth Capital raised their price target on shares of Ligand Pharmaceuticals (NASDAQ:LGND) from $51.00 to $65.00 in a research note to investors on Wednesday, July 24th. They now have a “buy” rating on the stock.
One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $55.50.
Ligand Pharmaceuticals (NASDAQ:LGND) traded down 0.02% during mid-day trading on Wednesday, hitting $47.04. The stock had a trading volume of 212,553 shares. Ligand Pharmaceuticals has a one year low of $14.75 and a one year high of $50.85. The stock’s 50-day moving average is $45.84 and its 200-day moving average is $33.82. The company has a market cap of $961.5 million and a price-to-earnings ratio of 111.76.
Ligand Pharmaceuticals (NASDAQ:LGND) last released its earnings data on Thursday, August 1st. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.01. The company had revenue of $9.58 million for the quarter, compared to the consensus estimate of $9.48 million. Ligand Pharmaceuticals’s revenue was up 66.8% compared to the same quarter last year. On average, analysts predict that Ligand Pharmaceuticals will post $0.51 earnings per share for the current fiscal year.
In other Ligand Pharmaceuticals news, VP Charles Berkman sold 28,323 shares of Ligand Pharmaceuticals stock on the open market in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $47.54, for a total transaction of $1,346,475.42. Following the sale, the vice president now directly owns 26,936 shares of the company’s stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is a biotechnology company that operates with a business model focused on developing or acquiring assets.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.